Market Overview

Intersect ENT: Q3 Earnings Insights



Shares of Intersect ENT (NASDAQ:XENT) remained unaffected after the company reported Q3 results.

Quarterly Results

Earnings per share increased 17.07% year over year to ($0.34), which beat the estimate of ($0.45).

Revenue of $22,720,000 declined by 5.55% from the same period last year, which beat the estimate of $21,370,000.


Intersect ENT hasn't issued any earnings guidance for the time being.

Q4 revenue expected to be between $26,991,000 and $28,579,000.

Conference Call Details

Date: Nov 02, 2020

Time: 08:30 AM

ET Webcast URL:

Price Action

Company's 52-week high was at $31.46

52-week low: $5.97

Price action over last quarter: down 20.72%

Company Profile

Intersect ENT Inc are a commercial drug delivery company committed to improving the quality of life for patients with ear, nose and throat conditions. It offer's PROPEL and PROPEL mini drug-releasing implants for patients undergoing sinus surgery to treat chronic sinusitis and PROPEL contour, a steroid-releasing implant to frontal and maxillary sinus ostia or openings of the dependent sinuses. The company generates revenues from the sale of our PROPEL family of products.


Related Articles (XENT)

View Comments and Join the Discussion!

Posted-In: Earnings News